Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of May 2026, specifically dated May 12, 2026. The report discloses significant corporate governance changes regarding the executive leadership of the company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- CEO Retirement: Dr. Andrea Pfeifer announced her retirement as Chief Executive Officer after 23 years of service. The retirement is effective at the next Annual General Meeting (AGM) on June 11, 2026.
- Reason for Departure: The retirement is voluntary to spend more time with family and is not due to any disagreement with the company regarding operations, policies, or practices.
- Interim Leadership: Dr. Martin Zügel, the current Chair of the Board, has been appointed as Interim CEO to lead the company during the search for a permanent successor.
- Transition Roles: Dr. Pfeifer will serve as an Advisor to facilitate the transition and will be appointed as Honorary Chair of the Board and Co-Chair of the Scientific Advisory Board.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, market outlook, or specific risk factors. Management commentary is limited to the announcement of the leadership transition and the appointment of an industry consultant to conduct the CEO search. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Confirm the exact date of the AGM (June 11, 2026) when the CEO transition becomes official.
- Review the attached Press Release (Exhibit 99.1) for additional details on the transition plan.
- Monitor future filings for the announcement of the permanent CEO successor.
- Verify Dr. Martin Zügel's background and tenure as Chair of the Board in the most recent Form 20-F.